There was no significant difference in change in WOMAC symptoms, knee VAS pain, depression scores, utility scores, and serum levels of IL6 and hs-CRP between vitamin D and placebo groups after 3 years of cessation of the clinical trial (Table 2). This evidence concerns the gene IL6 and depressive disorder.